close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

2.100 -0.050 (-2.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 499,085
Open 2.150
Bid (Size) 2.110 (5,400)
Ask (Size) 2.120 (2,000)
Prev. Close 2.150
Today's Range 2.080 - 2.170
52wk Range 1.330 - 2.610
Shares Outstanding 31,056,238
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
From Inhibikase Therapeutics
Via GlobeNewswire

Performance

YTD
+7.7%
+7.7%
1 Month
-16.0%
-16.0%
3 Month
+12.3%
+12.3%
6 Month
+28.8%
+28.8%
1 Year
+29.6%
+29.6%

More News

Read More
News headline image
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum ↗
Via Chartmill
News headline image
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Inhibikase Posts Wider Loss in Q2 ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Inhibikase Therapeutics, Inc. - Common Stock publicly traded?
Yes, Inhibikase Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Inhibikase Therapeutics, Inc. - Common Stock trade on?
Inhibikase Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock?
The ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock is IKT on the Nasdaq Stock Market
What is the current price of Inhibikase Therapeutics, Inc. - Common Stock?
The current price of Inhibikase Therapeutics, Inc. - Common Stock is 2.100
When was Inhibikase Therapeutics, Inc. - Common Stock last traded?
The last trade of Inhibikase Therapeutics, Inc. - Common Stock was at 09/24/26 04:00 PM ET
What is the market capitalization of Inhibikase Therapeutics, Inc. - Common Stock?
The market capitalization of Inhibikase Therapeutics, Inc. - Common Stock is 65.22M
How many shares of Inhibikase Therapeutics, Inc. - Common Stock are outstanding?
Inhibikase Therapeutics, Inc. - Common Stock has 65M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.